Sanofi
41.60USD
-0.3600 (-0.86%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on SNY.
Revenue
| (EUR) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 40.6B | 41.6B | 44.3B | 46.7B | 47.6B | 50.7B |
| Q1 | — | — | — | — | 11.2B | — |
| Q2 | — | — | — | 10.7B | 12.3B | — |
| Q3 | — | — | — | 13.2B | 13.3B | — |
| Q4 | — | — | — | 12.2B | 12.8B | — |
Revenue
| (EUR) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 2.69 | 2.15 | 2.29 | 3.19 | 4.90 | 5.23 |
| Q1 | — | — | — | — | .670 | — |
| Q2 | — | — | — | 1.62 | .145 | — |
| Q3 | — | — | — | 1.15 | 1.51 | — |
| Q4 | — | — |
Fiscal period: Reported, Estimated. Reported figures: Yahoo Finance (limited history). Estimates are sell-side consensus for periods that have not reported. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| — |
| -.330 |
| 1.12 |
| — |
Debt level and coverage